Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Rock Paper Shotgun3d
More than 6,700 people bought the false N95 face mask from Razer - and now they're getting refunds
Thousands of customers who bought the glimmering "N95" face mask from Razer during the Covid-19 pandemic are finally getting ...
$1 million in refunds are on their way to those who picked up Razer's not-actually-N95 Zephyr mask
R emember Razer's Zephyr mask? Yeah, the one with the RGB lighting, the black colourway that went with everything in my ...
CNET3d
Razer Is Sending Out Checks for Its Falsely Labeled N95 Zephyr Masks
FTC sued Razer, a gaming and lifestyle company, after the company sold the Zephyr mask as an N95-equivalent mask. N95 masks ...